MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

@article{Fessler2009MUC1IA,
  title={MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells},
  author={S. Fessler and Mark T. Wotkowicz and S. Mahanta and C. Bamdad},
  journal={Breast Cancer Research and Treatment},
  year={2009},
  volume={118},
  pages={113-124}
}
In the United States, 211,000 women are diagnosed each year with breast cancer. Of the 42,000 breast cancer patients who overexpress the HER2 growth factor receptor, <35% are responsive to treatment with the HER2-disabling antibody, called trastuzumab (Herceptin). Despite those statistics, women diagnosed with breast cancer are now tested to determine how much of this important growth factor receptor is present in their tumor because patients whose treatment includes trastuzumab are three-times… Expand
Role of trastuzumab in the management of HER2-positive metastatic breast cancer.
TLDR
Pharmacology, efficacy studies, and toxicities of trastuzumab in metastatic breast cancer, and some insights on resistance to therapy are provided. Expand
Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models.
TLDR
Induced resistance to trastuzumab monotherapy can be overcome by a combination of trastzumab and granulocyte colony stimulating factor or chemotherapy, and appears to involve the host's immune system and antibody-dependent cellular cytotoxicity. Expand
Mechanisms of resistance to trastuzumab: an updated review
TLDR
This review describes several important well-known trastuzumab resistance mechanisms as well as the updated advancement in this field. Expand
Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review
TLDR
Clinicians are being continuously challenged by the resistance mechanisms and bioavailability of the drugs in the treatment of metastatic breast cancers, and the addition of new drugs to the chemotherapeutic regimen increases the complexity, burden of side effects, and chances of relapse. Expand
Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
TLDR
A preclinical model of human ovarian cancer cells, SKOV-3, developed and examined the corresponding changes in gene expression revealed the differential expression of genes potentially involved in angiogenesis, metastasis, differentiation and proliferation, such as mucin1 (MUC1) as well as the potential mechanisms of acquired therapeutic resistance to trastuzumab. Expand
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
TLDR
This review focuses on mechanisms of intrinsic and/or acquired resistance to HER2-targeted therapies that have been identified in preclinical and clinical studies. Expand
Primary trastuzumab resistance: new tricks for an old drug
TLDR
It is proposed that the conventional definition of resistance as it pertains to trastuzumab and, perhaps, to other targeted therapeutics, may require revision. Expand
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
TLDR
The molecular and cellular factors that contribute to the pathophysiology of HER2 in breast cancer, as well as the landmark preclinical and clinical findings underlying the approval and use of pertuzumab in the neoadjuvant setting, are reviewed. Expand
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
TLDR
This paper summarizes existing preclinical and clinical evidence on the mechanisms of trastuzumab action and resistance and provides an up-to-date overview of novel HER2-directed therapies in clinical development. Expand
Targeting HER2 for the treatment of breast cancer.
TLDR
Combinations of these drugs to more completely inhibit the HER receptor layer, or combining HER2-targeted agents with agents that target downstream signaling, alternative pathways, or components of the host immune system, are being vigorously investigated in the preclinical and clinical settings. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
TLDR
The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year. Expand
Trastuzumab: triumphs and tribulations
TLDR
Despite its initial efficacy, acquired resistance to trastuzumab develops in a majority of patients with MBC, and a large subset never responds, demonstrating primary resistance. Expand
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
TLDR
Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance, and this study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of her2 and Met. Expand
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
TLDR
The current knowledge on the preclinical and clinical evidence about the mechanism of action of trastuzumab and on the mechanisms underlying the development of resistance are summarized and their possible clinical implications are discussed. Expand
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
  • M. Cobleigh, C. Vogel, +8 authors D. Slamon
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Expand
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
TLDR
Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab. Expand
Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
  • H. Yamauchi, A. O'neill, +4 authors D. Hayes
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
Pretreatment circulating NRP levels predict a low likelihood of benefit from HT, specifically DRO, in patients with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive or receptor-unknown metastatic breast cancer, even when adjusted for other known predictive factors. Expand
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
TLDR
Findings suggests that vinorelbine-based combinations are active and should be further evaluated in studies conducted in trastuzumab-resistant patients, including those evaluating newer HER2-targeting agents. Expand
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
TLDR
Preoperative trastuzumab plus vinorelbine is active and well tolerated in patients with HER2-positive, operable, stage II/III breast cancer andHER2-overexpressing tumors with a basal-like phenotype, or with expression of insulin-like growth factor-I receptor and other proteins involved in growth factor pathways, are more likely to be resistant to this regimen. Expand
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
TLDR
In breast cancer cell models that overexpress HER2/neu, an increased level of IGF-IR signaling appears to interfere with the action of trastuzumab, and strategies that target IGF- IR signaling may prevent or delay development of resistance to trastzumab. Expand
...
1
2
3
4
5
...